Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis

doi:10.4254/wjh.v14.i2.411

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3822)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

182

WORD

HTML

1546

Figures (1-1)

215

Tables (1-2)

224

Sum=2230

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

374

Download

1218

Sum=1592

Feb 27, 2022 (publication date) through Jul 25, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Feb 27, 2022; 14(2): 411-419
Published online Feb 27, 2022. doi: 10.4254/wjh.v14.i2.411

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan-Meier curves for development of cirrhosis based on medication use.

Citation: Ramsey ML, Wellner MR, Porter K, Kirkby SE, Li SS, Lara LF, Kelly SG, Hanje AJ, Sobotka LA. Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis. World J Hepatol 2022; 14(2): 411-419
URL: https://www.wjgnet.com/1948-5182/full/v14/i2/411.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i2.411